Long-acting injectable form of HIV prevention outperforms daily pill in NIH study
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among ...
Jul 7, 2020
0
1